A pipeline full of cures

The enormous unmet medical need represented by Lumen’s initial targets also demonstrates the size of its addressable markets.

Moving
Fast To Save
Millions
Of Lives

Oral biologic drugs are the fastest, safest, best way to generate new cures for many highly prevalent diseases that the conventional drug-making toolkit have failed to solve. This is particularly true for addressing unintended consequences of antibiotics and improving access to medicines in the developing world, but drug shortages are also a problem in the developed world for highly prevalent diseases like obesity and diabetes. Lumen’s technology offers new hope to these left-behind patients.

Pipeline

Disease Area
Mode of Action
MOA Previously
Demonstrated
Preclinical Phase 1
(safety) Phase 2
(proof of
concept) Phase 3
(definitive
efficacy)
Research &
Funding
Partners
Core pipeline
Product Candidate

C. difficile Colitis

(Clostridioides difficile)

Initiated Spring 2018
Mode of action: Cocktail of biologics; two formats
Phase 1
Traditionally considered a hospital-acquired infection, C. difficile is  more commonly community - required today. For this reason, the shelf-stable, orally delivered format of Lumen’s product is an important addition to the tool kit for treating and preventing this disease. Long-term consequences include chronic diarrhea, severe intestinal inflammation, surgical resection, and death. Insidiously, the very thing that is used to treat this infection—broad spectrum antibiotics—is also the thing that causes the disease.  . C. difficile therefore appears at the top of the CDC’s antimicrobial threats list year after year, and in 2009 was estimated to single-handedly drive 2.3% of all US hospital costs.
Product Candidate

C. difficile Colitis

(Clostridioides difficile)

Initiated Spring 2018
Mode of action: Cocktail of biologics; two formats
Phase 1
Traditionally considered a hospital-acquired infection, C. difficile is  more commonly community - required today. For this reason, the shelf-stable, orally delivered format of Lumen’s product is an important addition to the tool kit for treating and preventing this disease. Long-term consequences include chronic diarrhea, severe intestinal inflammation, surgical resection, and death. Insidiously, the very thing that is used to treat this infection—broad spectrum antibiotics—is also the thing that causes the disease.  . C. difficile therefore appears at the top of the CDC’s antimicrobial threats list year after year, and in 2009 was estimated to single-handedly drive 2.3% of all US hospital costs.
Product Candidate

IBD

(Crohn's disease and ulcerative colitis)

Initiated Summer 2021
Mode of action: Biologic cocktail
Preclinical
Inflammatory bowel disease (IBD) is a systemic autoimmune disease, but it has an obvious nexus with the gastrointestinal tract. The two main sub-varieties—Crohn’s disease and ulcerative colitis—have many available treatments on the market today, but it remains a major unmet medical need: current treatments are costly, require inconvenient injection delivery, and come with severe side effects. There are no approved therapies at all for mild-to-moderate Crohn’s. A safe, affordable, orally delivered drug to root out IBD at its source is a straightforward application of Lumen's technology, and would constitute a major advance for the field.
Product Candidate

Metabolic Disease

(Cardiometabolic Disease)

Initiated Spring 2021
Mode of action: Metabolic signaling
Preclinical
Cardiometabolic disease (CMD)—a cluster of related conditions that includes obesity, diabetes, and cardiovascular disease—afflicts hundreds of millions of people worldwide, and the associated health and economic burdens continue to grow. An estimated 17.9 million people died from CMD in 2019, representing nearly a third of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Today, over three quarters of deaths from cardiovascular diseases take place in low- and middle-income countries. Lumen is collaborating with Novo Nordisk, a global leader in CMD, to develop metabolically active molecules produced and delivered using spirulina.
Innovation pipeline
Product Candidate

C. difficile Colitis

(Clostridioides difficile)

Initiated Spring 2018
Mode of action: Cocktail of biologics; two formats
Phase 1
Traditionally considered a hospital-acquired infection, C. difficile is  more commonly community - required today. For this reason, the shelf-stable, orally delivered format of Lumen’s product is an important addition to the tool kit for treating and preventing this disease. Long-term consequences include chronic diarrhea, severe intestinal inflammation, surgical resection, and death. Insidiously, the very thing that is used to treat this infection—broad spectrum antibiotics—is also the thing that causes the disease.  . C. difficile therefore appears at the top of the CDC’s antimicrobial threats list year after year, and in 2009 was estimated to single-handedly drive 2.3% of all US hospital costs.
Product Candidate

Covid-19

(SARS-CoV-2)

Initiated Summer 2020
Mode of action: Neutralizing antibody cocktail
IND Prep
Covid-19 is widely known as a respiratory disease, but its GI symptoms are well documented. The now-famous ACE2 receptor is abundantly expressed on the cells lining the GI tract, and over half of Covid-19 sufferers show symptoms of GI distress, and up to a quarter show only GI symptoms. GI infection by the virus can have serious long-term effects, and high enteric viral loads are thought to contribute to fatalities from acute respiratory distress syndrome (ARDS) and wet-lung disease. Lumen’s Covid-19 product is designed to block GI infection and rapidly flush the virus from the GI tract, thereby reducing disease symptoms and potentially reducing transmission rates.
Product Candidate

C. difficile Colitis

(Clostridioides difficile)

Initiated Spring 2018
Mode of action: Cocktail of biologics; two formats
Phase 1
Traditionally considered a hospital-acquired infection, C. difficile is  more commonly community - required today. For this reason, the shelf-stable, orally delivered format of Lumen’s product is an important addition to the tool kit for treating and preventing this disease. Long-term consequences include chronic diarrhea, severe intestinal inflammation, surgical resection, and death. Insidiously, the very thing that is used to treat this infection—broad spectrum antibiotics—is also the thing that causes the disease.  . C. difficile therefore appears at the top of the CDC’s antimicrobial threats list year after year, and in 2009 was estimated to single-handedly drive 2.3% of all US hospital costs.

Obesity

Mode of Action: Oral biologic

MOA Previously Demonstrated:

Preclinical:

C. difficile (LMN-201)

Mode of Action: Oral biologic cocktail

MOA Previously Demonstrated:

Preclinical:

Research & Funding Partners

IBD (Crohn’s/UC)

Mode of Action: Oral biologic cocktail

MOA Previously Demonstrated:

Preclinical:

Kidney stone disease

Mode of Action: Oral biologic cocktail

MOA Previously Demonstrated:

Preclinical:

Research & Funding Partners:

Gastroenteritis

Mode of Action: Antibody coctail

MOA Previously Demonstrated:

Preclinical:

Research & Funding Partners:

Influenza & Covid-19

Mode of Action: Intranasal biologic

MOA Previously Demonstrated:

Preclinical:

Research & Funding Partners:

Malaria

Mode of Action: Intranasal vaccine

MOA Previously Demonstrated:

Preclinical:

Research & Funding Partners: